HK1137758A1 - Inhibitors of akt activity akt - Google Patents
Inhibitors of akt activity aktInfo
- Publication number
- HK1137758A1 HK1137758A1 HK10102928.1A HK10102928A HK1137758A1 HK 1137758 A1 HK1137758 A1 HK 1137758A1 HK 10102928 A HK10102928 A HK 10102928A HK 1137758 A1 HK1137758 A1 HK 1137758A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- akt
- inhibitors
- activity
- akt activity
- activity akt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87319806P | 2006-12-06 | 2006-12-06 | |
US88066107P | 2007-01-16 | 2007-01-16 | |
US96787207P | 2007-09-06 | 2007-09-06 | |
PCT/US2007/024722 WO2008070016A2 (en) | 2006-12-06 | 2007-12-03 | Inhibitors of akt activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1137758A1 true HK1137758A1 (en) | 2010-08-06 |
Family
ID=39492823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10102928.1A HK1137758A1 (en) | 2006-12-06 | 2010-03-19 | Inhibitors of akt activity akt |
Country Status (30)
Country | Link |
---|---|
US (3) | US7576209B2 (es) |
EP (1) | EP2104669B1 (es) |
JP (2) | JP4431636B1 (es) |
KR (1) | KR101110598B1 (es) |
CN (1) | CN101600706B (es) |
AR (1) | AR064010A1 (es) |
AU (1) | AU2007328286B2 (es) |
BR (1) | BRPI0719580A2 (es) |
CA (1) | CA2670760C (es) |
CL (1) | CL2007003495A1 (es) |
CO (1) | CO6190528A2 (es) |
CR (1) | CR10851A (es) |
EA (1) | EA016195B1 (es) |
EC (1) | ECSP099376A (es) |
ES (1) | ES2527567T3 (es) |
GE (1) | GEP20125469B (es) |
GT (1) | GT200900146A (es) |
HK (1) | HK1137758A1 (es) |
HN (1) | HN2009001112A (es) |
IL (2) | IL198826A (es) |
MA (1) | MA31027B1 (es) |
MX (1) | MX2009006052A (es) |
NI (1) | NI200900106A (es) |
NO (1) | NO20092569L (es) |
NZ (2) | NZ577470A (es) |
PE (1) | PE20081341A1 (es) |
SV (1) | SV2009003283A (es) |
TN (1) | TN2009000224A1 (es) |
TW (1) | TWI386410B (es) |
WO (2) | WO2008070016A2 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ563423A (en) * | 2005-06-10 | 2010-05-28 | Merck Sharp & Dohme | Inhibitors of AKT activity |
US20100022573A1 (en) * | 2006-12-06 | 2010-01-28 | Layton Mark E | Inhibitors of akt activity |
AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
CA2726317A1 (en) * | 2008-06-03 | 2009-12-10 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
US8536193B2 (en) * | 2008-06-03 | 2013-09-17 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
CA2729412A1 (en) | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co., Ltd. | Novel spirochromanone carboxylic acids |
CA2733533C (en) | 2008-08-25 | 2013-12-17 | Irm Llc | Hedgehog pathway modulators |
DE102008043724A1 (de) * | 2008-11-13 | 2010-05-20 | Biotronik Vi Patent Ag | Erhöhung der Effizienz pharmazeutische Wirkstoffe-freisetzender Medizinprodukte durch Kombination mit einem Inhibitor des Transportproteins P-Glycoprotein |
CA2750051A1 (en) * | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JP2012516900A (ja) | 2009-02-05 | 2012-07-26 | トーカイ ファーマシューティカルズ,インク. | ステロイド性cyp17阻害剤/抗アンドロゲン剤の新しいプロドラッグ |
WO2010101734A1 (en) | 2009-03-06 | 2010-09-10 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an akt inhibitor and other anticancer agents |
US8168652B2 (en) | 2009-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JP5567136B2 (ja) | 2009-09-08 | 2014-08-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 4−置換ピリジン−3−イル−カルボキサミド化合物及び使用方法 |
EP2473495A1 (en) | 2009-09-18 | 2012-07-11 | Almac Discovery Limited | Pharmaceutical compounds |
GB0919380D0 (en) | 2009-11-04 | 2009-12-23 | Almac Discovery Ltd | Pharmaceutical compouds |
GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
EP2572199B1 (en) | 2010-05-21 | 2017-03-08 | Novartis AG | Combination |
CN103097384B (zh) * | 2010-07-12 | 2017-02-15 | 拜耳知识产权有限责任公司 | 取代的咪唑并[1,2‑a]嘧啶和吡啶 |
US20130184273A1 (en) | 2010-07-13 | 2013-07-18 | Bayer Intellectual Property Gmbh | Bicyclic pyrimidines |
CN103384670B (zh) | 2010-07-28 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的咪唑并[1,2-b]哒嗪 |
JP5886868B2 (ja) * | 2010-12-16 | 2016-03-16 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換ピリミド[1,2−b]インダゾールおよびPI3K/AKT経路のモジュレーターとしてのそれらの使用 |
WO2012097021A1 (en) | 2011-01-11 | 2012-07-19 | Glaxosmithkline Llc | Combination |
PL2698372T3 (pl) | 2011-04-06 | 2016-07-29 | Taiho Pharmaceutical Co Ltd | Nowy związek imidazooksazynowy lub jego sól |
JO3068B1 (ar) * | 2011-04-07 | 2017-03-15 | Bayer Ip Gmbh | إيميدازوبيريميدينات كمثبطات كيناز akt |
WO2012177852A1 (en) * | 2011-06-24 | 2012-12-27 | Arqule, Inc | Substituted imidazopyridinyl compounds |
CN103748093B (zh) * | 2011-06-24 | 2016-06-01 | 艾科尔公司 | 被取代的咪唑并吡啶基-氨基吡啶化合物 |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
US9260435B2 (en) | 2012-01-10 | 2016-02-16 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines as Akt kinase inhibitors |
CN104066736B (zh) | 2012-01-10 | 2017-03-08 | 拜耳知识产权有限责任公司 | 作为akt激酶抑制剂的取代的吡唑并嘧啶 |
US9433659B2 (en) | 2012-01-20 | 2016-09-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Enhanced glycemic control using Ad36E4orf1 and AKT1 inhibitor |
GB201205164D0 (en) | 2012-03-23 | 2012-05-09 | Almac Discovery Ltd | Pharmaceutical compounds |
JP5855250B2 (ja) | 2012-07-02 | 2016-02-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
BR112015023098A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Jefferson | agentes de infrarregulação do receptor de andrógeno e usos dos mesmos |
WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
JP2016528252A (ja) | 2013-08-12 | 2016-09-15 | トーカイ ファーマシューティカルズ, インコーポレイテッド | アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー |
EP3052098B1 (en) | 2013-10-01 | 2020-12-02 | Novartis AG | Enzalutamide in combination with afuresertib for the treatment of prostate cancer |
RU2016116915A (ru) | 2013-10-01 | 2017-11-13 | Новартис Аг | Комбинация |
WO2015094928A1 (en) * | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Liposomal compositions for allosteric akt inhibitors |
AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
KR20160127754A (ko) | 2014-03-12 | 2016-11-04 | 노파르티스 아게 | Btk 억제제 및 akt 억제제를 포함하는 조합물 |
WO2015142605A2 (en) | 2014-03-17 | 2015-09-24 | Merck Sharp & Dohme Corp. | Polymeric nanoparticles and methods of making and using same |
WO2016136928A1 (ja) | 2015-02-27 | 2016-09-01 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
FR3033499A1 (fr) | 2015-03-11 | 2016-09-16 | Centre Leon-Berard | Composition pour le traitement des tumeurs neuroendocrines pancreatiques |
US10793582B2 (en) | 2015-10-22 | 2020-10-06 | Mitsubishi Tanabe Pharma Corporation | Bicyclic heterocyclic compound |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
CN108426971B (zh) * | 2018-03-09 | 2020-03-20 | 浙江中一检测研究院股份有限公司 | 一种快速检测水中微囊藻毒素的方法 |
CN115956078A (zh) * | 2020-05-08 | 2023-04-11 | 乔治穆内有限责任公司 | Akt3调节剂及其使用方法 |
WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040106540A1 (en) * | 2001-04-10 | 2004-06-03 | Barnett Stanley F | Method of treating cancer |
WO2002083138A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003086279A2 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
CA2480880C (en) | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
EP1496896A4 (en) | 2002-04-08 | 2007-10-31 | Merck & Co Inc | AKT INHIBITORS EFFECT |
WO2003086404A1 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
DE60336576D1 (de) | 2002-10-30 | 2011-05-12 | Merck Sharp & Dohme | Hemmer der akt aktivität |
WO2004096131A2 (en) | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
US7638530B2 (en) * | 2003-04-24 | 2009-12-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
CN1809536A (zh) | 2003-04-24 | 2006-07-26 | 麦克公司 | Akt活性抑制剂 |
WO2004096129A2 (en) | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
JP2007008816A (ja) * | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
EP1679308B1 (en) * | 2003-10-15 | 2013-07-24 | Ube Industries, Ltd. | Novel indazole derivative |
DE602005026509D1 (de) | 2004-04-09 | 2011-04-07 | Merck Sharp & Dohme | Hemmer der akt aktivität |
WO2005100356A1 (en) | 2004-04-09 | 2005-10-27 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2006036395A2 (en) * | 2004-08-23 | 2006-04-06 | Merck & Co., Inc. | Inhibitors of akt activity |
US20080015212A1 (en) | 2004-12-02 | 2008-01-17 | Barnett Stanley F | Inhibitors Of Akt Activity |
CA2589084A1 (en) | 2004-12-15 | 2006-06-22 | Merck & Co., Inc. | Inhibitors of akt activity |
CN101115479A (zh) | 2005-02-14 | 2008-01-30 | 默克公司 | Akt活性抑制剂 |
WO2006110638A2 (en) * | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Inhibitors of akt activity |
NZ563423A (en) | 2005-06-10 | 2010-05-28 | Merck Sharp & Dohme | Inhibitors of AKT activity |
MX2008009475A (es) * | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
AU2008236670B2 (en) * | 2007-04-05 | 2011-12-01 | Amgen Inc. | Aurora kinase modulators and method of use |
-
2007
- 2007-11-28 AR ARP070105281A patent/AR064010A1/es active IP Right Grant
- 2007-11-29 TW TW096145487A patent/TWI386410B/zh not_active IP Right Cessation
- 2007-11-30 PE PE2007001698A patent/PE20081341A1/es not_active Application Discontinuation
- 2007-12-03 KR KR1020097011729A patent/KR101110598B1/ko not_active IP Right Cessation
- 2007-12-03 BR BRPI0719580-0A patent/BRPI0719580A2/pt active Search and Examination
- 2007-12-03 WO PCT/US2007/024722 patent/WO2008070016A2/en active Application Filing
- 2007-12-03 NZ NZ577470A patent/NZ577470A/en not_active IP Right Cessation
- 2007-12-03 JP JP2009540243A patent/JP4431636B1/ja not_active Expired - Fee Related
- 2007-12-03 AU AU2007328286A patent/AU2007328286B2/en not_active Ceased
- 2007-12-03 GE GEAP200711349A patent/GEP20125469B/en unknown
- 2007-12-03 MX MX2009006052A patent/MX2009006052A/es active IP Right Grant
- 2007-12-03 EA EA200970542A patent/EA016195B1/ru not_active IP Right Cessation
- 2007-12-03 EP EP07862428.5A patent/EP2104669B1/en active Active
- 2007-12-03 CN CN2007800509679A patent/CN101600706B/zh not_active Expired - Fee Related
- 2007-12-03 WO PCT/US2007/024772 patent/WO2008070041A2/en active Application Filing
- 2007-12-03 ES ES07862428.5T patent/ES2527567T3/es active Active
- 2007-12-03 CA CA2670760A patent/CA2670760C/en not_active Expired - Fee Related
- 2007-12-03 NZ NZ595829A patent/NZ595829A/xx not_active IP Right Cessation
- 2007-12-04 US US11/999,234 patent/US7576209B2/en active Active
- 2007-12-04 CL CL200703495A patent/CL2007003495A1/es unknown
-
2009
- 2009-05-19 IL IL198826A patent/IL198826A/en not_active IP Right Cessation
- 2009-05-28 CO CO09054952A patent/CO6190528A2/es active IP Right Grant
- 2009-05-29 NI NI200900106A patent/NI200900106A/es unknown
- 2009-06-01 EC EC2009009376A patent/ECSP099376A/es unknown
- 2009-06-02 GT GT200900146A patent/GT200900146A/es unknown
- 2009-06-02 HN HN2009001112A patent/HN2009001112A/es unknown
- 2009-06-03 SV SV2009003283A patent/SV2009003283A/es unknown
- 2009-06-03 TN TNP2009000224A patent/TN2009000224A1/fr unknown
- 2009-06-05 JP JP2009135908A patent/JP5364454B2/ja not_active Expired - Fee Related
- 2009-06-09 CR CR10851A patent/CR10851A/es not_active Application Discontinuation
- 2009-06-10 US US12/482,095 patent/US20090253734A1/en not_active Abandoned
- 2009-06-26 MA MA32047A patent/MA31027B1/fr unknown
- 2009-07-06 NO NO20092569A patent/NO20092569L/no not_active Application Discontinuation
-
2010
- 2010-03-19 HK HK10102928.1A patent/HK1137758A1/xx not_active IP Right Cessation
- 2010-04-21 IL IL205220A patent/IL205220A0/en not_active IP Right Cessation
-
2011
- 2011-03-11 US US13/046,322 patent/US8288407B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1137758A1 (en) | Inhibitors of akt activity akt | |
HK1132676A1 (en) | Inhibitors of akt activity akt | |
HK1225722A1 (zh) | 激酶活性抑製劑 | |
HRP20130429T1 (en) | Inhibitors of akt activity | |
EP1968568A4 (en) | HEMMER OF NUTS ACTIVITY | |
IL190968A0 (en) | Inhibitors of akt activity | |
EP1850843A4 (en) | ACTIVITY INHIBITORS OF AKT | |
EP2303269A4 (en) | HAMMER OF ACT ACTIVITY | |
EP1871376A4 (en) | INHIBITOR OF AKT ACTIVITY | |
EP2114388A4 (en) | INHIBITORS OF AKT'S ACTIVITY | |
EP1720855A4 (en) | HEMMER OF ACT ACTIVITY | |
EP1784175A4 (en) | INHIBITORS OF ACT ACTIVITY | |
EP1737861A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP1827436A4 (en) | ACTIVITY INHIBITORS AKT | |
EP2391623A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP2134175A4 (en) | HAMMER OF ACT ACTIVITY | |
IL209488A0 (en) | Inhibitors of akt activity | |
EP2120951A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP2406250A4 (en) | HAMMER OF ACT ACTIVITY | |
EP2306825A4 (en) | HAMMER OF ACT ACTIVITY | |
EP2303852A4 (en) | ACTIVITY INHIBITORS AKT | |
EP1824849A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP2405756A4 (en) | HAMMER OF ACT ACTIVITY | |
EP2516435B8 (en) | Inhibitors of akt activity | |
EP1948185A4 (en) | INHIBITORS OF AKT ACTIVITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171203 |